Clinical usefulness of serum Mac-2 binding protein glycosylation isomer (M2BPGi) as a novel biomarker in respiratory diseases

Clinical usefulness of serum Mac-2 binding protein glycosylation isomer (M2BPGi) as a novel biomarker in respiratory diseases - Serum M2BPGi in respiratory diseases

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000022606

Enrollment

200

Registered

2016-06-04

Start date

2015-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory diseases

Interventions

serum M2BPGi pulmonary function test FeNO Chest HRCT Impedance by forced oscillation technique (FOT)

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients with respiratory diseases such as asthma, COPD and interstitial pneumonia

Exclusion criteria

Exclusion criteria: Patients who are unable to get informed consent

Design outcomes

Primary

Measure	Time frame
Comparison of serum M2BPGi level between respiratory diseases (e.g. asthma, COPD, interstitial pneumonia) and normal control	—

Secondary

Measure	Time frame
To investigate correlation between serum M2BPGi and clinical characteristics, pulmonary function tests, FeNO, Chest HRCT findings in respiratory diseases.	—

Countries

Japan

Contacts

Public ContactTomoyuki Fujisawa

Hamamatsu University School of Medicine Second Division, Department of Internal Medicine

fujisawa@hama-med.ac.jp053-435-2263

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026